April 13, 2024, CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical stage biotechnology company aims to use the innovative gene editing technology to help people with severe diseases, announced an oral presentation and 3 poster presentations at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually.
Dr. Peixue(Jason) Li, Head of Translational Science of Correctseq will participate in this conference and give an oral presentation titled “Development of Best-in-Class Gene Editing Therapy for β-Hemoglobinopathies Using Innovative Transformer Base Editor (tBE)” on May 9, at 2:15 pm - 2:30 pm, EST.
Session Title: Correction of Genetic Disorders of the Blood and Immune System
Session Date/Time: Thursday May 9, 2024 1:30 PM-3:15 PM, EST
Presentation Title: Development of Best-in-Class Gene Editing Therapy for β-Hemoglobinopathies Using Innovative Transformer Base Editor (tBE)
Speaker: Peixue(Jason) Li, Ph.D., Head of Translational Science, Correctseq
Presentation Time: 2:15 PM-2:30 PM, EST
Room: 314-317
Abstract Number: 173
Format: Oral presentation
Session Title: Wednesday Posters: Base Editing and Prime Editing
Session Date/Time: Wednesday May 8, 2024 12:00 PM, EST
Poster Title: Innovative Transformer Base Editor (tBE)-Mediated Undetected Off-Target Base Editing and Its Potential Clinical Applications for Unmet Medical Needs
Presentation Room: Exhibit Hall
Abstract Number: 688
Format: Poster
Session Title: Wednesday Posters: Metabolic Diseases
Session Date/Time: Wednesday May 8, 2024 12:00 PM, EST
Poster Title: Precise Base Editing of Hyperlipidemia-Associated Genes by the Transformer Base Editor to Reduce Blood Lipid Levels
Presentation Room: Exhibit Hall
Abstract Number: 585
Format: Poster
Session Title: Thursday Posters: Immune Targeting and Approaches with Genetically-Modified Cells and Cell Therapies
Session Date/Time: Thursday May 9, 2024 12:00 PM, EST
Poster Title: Efficient Genome Editing of Human T Cells with Innovative Transformer Base Editor (tBE) for Construction of Next Generation CAR-T Therapies
Presentation Room: Exhibit Hall
Abstract Number: 1315
Format: Poster
For more information about the meeting, visit: https://annualmeeting.asgct.org/
About CorrectSequence Therapeutics
CorrectSequence TherapeuticsTM (CorrectseqTM) (www.xmyhtsm.com) is a clinical stage biotechnology company aims to use our innovative gene editing technology to help people with severe diseases. We have developed multiple base editing systems and the transformer Base Editing (tBE) system with the best safety and efficacy performance is currently applied in all the IND enabling pipelines. Multiple pipelines for genetic diseases, cancer immunotherapy, metabolic diseases, infectious diseases are well underway. We are also working on novel target screening for tBE editing in ophthalmology and neurological diseases. We focus on biotechnology innovation, research and development and are committed to providing efficient, reliable and safe solution for unmet medical needs.
